Cisplatin
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Cisplatin: Drug Repurposing Evaluation Report
One-Sentence Summary
Cisplatin is a platinum-based antineoplastic agent widely used globally for the treatment of various solid tumours including testicular, ovarian, bladder, lung, and head and neck cancers. The TxGNN model has not generated any predicted new indications for cisplatin at this time, and critical data gaps (MOA details, package insert warnings) remain unresolved, preventing a full evaluation.
Quick Overview
| Item | Content |
|---|---|
| Drug Name (INN) | Cisplatin |
| DrugBank ID | DB00515 |
| Original Indication | Not available in evidence pack (well-known: testicular, ovarian, bladder, lung, head & neck cancers) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction has been made. The TxGNN model did not return any predicted new indications for cisplatin in this evaluation cycle. This may be due to several factors:
Cisplatin is one of the most extensively studied chemotherapy agents in oncology, with approved or established uses spanning a wide range of solid tumours. It is possible that the TxGNN model found no sufficiently novel disease–drug associations beyond cisplatin's already broad indication profile. Alternatively, the lack of Taiwan-specific regulatory data (0 authorizations, no package insert data integrated) may have limited the model's input features.
Currently, detailed mechanism of action data is not available in the evidence pack. Based on widely published pharmacological knowledge, cisplatin is a platinum coordination complex that forms intra- and inter-strand DNA crosslinks, inhibiting DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cells. This cytotoxic mechanism is non-selective across tumour types, which may also explain why the model did not identify a single standout repurposing candidate — cisplatin's mechanism is already broadly applied.
Clinical Trial Evidence
No predicted indication was generated by TxGNN; therefore, no targeted clinical trial search was performed for a new indication.
Currently no related clinical trials to report for a repurposing candidate.
Literature Evidence
No predicted indication was generated by TxGNN; therefore, no targeted literature search was performed for a new indication.
Currently no related literature to report for a repurposing candidate.
Taiwan Market Information
Cisplatin has no active marketing authorizations registered with TFDA in Taiwan (as of 2026-04-03).
No TFDA licenses found. Cisplatin products may need to be sourced through special import channels or clinical trial supply if needed in Taiwan.
Cytotoxicity
Cisplatin is a well-established conventional cytotoxic chemotherapy agent. The following profile is based on widely published pharmacological and clinical data:
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Platinum-based alkylating-like agent) |
| Myelosuppression Risk | High — dose-limiting myelosuppression; leukopenia, thrombocytopenia, and anaemia are common |
| Emetogenicity Classification | High (one of the most emetogenic chemotherapy agents; requires triple antiemetic prophylaxis) |
| Monitoring Items | CBC with differential, serum creatinine/BUN, creatinine clearance, electrolytes (Mg²⁺, K⁺, Ca²⁺, Na⁺), liver function tests, audiometry, neurological assessment |
| Handling Protection | Must follow cytotoxic drug handling regulations — closed-system transfer devices recommended; PPE (double gloving, gown, eye protection) required during preparation and administration |
Additional nephrotoxicity note: Cisplatin is well-known for dose-dependent nephrotoxicity. Aggressive intravenous hydration and monitoring of renal function are mandatory. Cumulative ototoxicity and peripheral neuropathy are also significant long-term concerns.
Safety Considerations
Safety data from the TFDA package insert and DDI databases was not available for this evaluation:
- Key Warnings: Data not available from TFDA sources — please refer to the package insert for safety information.
- Contraindications: Data not available from TFDA sources — please refer to the package insert for safety information.
- Drug Interactions: No interactions returned from DDI query (0 results).
⚠️ Data Gap (Blocking): TFDA package insert warnings and contraindications have not been parsed. This is classified as a blocking gap that prevents entry into Stage 1 safety preliminary assessment. Remediation: download and parse the package insert PDF from the TFDA website.
Data Gaps Summary
The following data gaps were identified and must be resolved before proceeding:
| Gap ID | Category | Item | Severity | Impact | Remediation |
|---|---|---|---|---|---|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | Blocking | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Affects mechanism–indication correlation analysis | Query DrugBank API for MOA data |
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model did not generate any predicted new indications for cisplatin. Combined with the absence of Taiwan marketing authorizations and unresolved blocking data gaps (TFDA package insert warnings), there is no actionable repurposing candidate to evaluate at this time.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Obtain and parse TFDA package insert for cisplatin to extract safety warnings and contraindications
- Resolve DG002 (High): Query DrugBank API for detailed mechanism of action data
- Re-run TxGNN prediction: After data gaps are resolved, re-run the TxGNN model with complete input features to determine if any new indications are predicted
- Investigate market status: Confirm whether cisplatin products are available in Taiwan through alternative channels (e.g., hospital special imports) despite having no active TFDA licenses
- Cross-reference other countries: Consider whether TxGNN predictions from other country sub-projects (if available) identified repurposing candidates for cisplatin that could be evaluated in the Taiwan context
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.